Trials / Completed
CompletedNCT00130364
Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 200 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 2 Years – 11 Years
- Healthy volunteers
- —
Summary
This study is not being conducted in the United States of America (USA). Atopic dermatitis, also called eczema, is characterized by redness, papulation (skin elevation) and pruritus (skin itching). The active ingredient of pimecrolimus inhibits T-cell activation. These cells are involved in the inflammatory component of the disease. This study will test the safety and efficacy of pimecrolimus cream 1% in atopic dermatitis of the face in patients intolerant of, or dependent on, topical corticosteroids.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pimecrolimus | Pimecrolimus 1 % cream |
| DRUG | Placebo | Pimecrolimus vehicle cream (placebo) |
Timeline
- Start date
- 2005-08-01
- Completion
- 2006-08-01
- First posted
- 2005-08-15
- Last updated
- 2008-01-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00130364. Inclusion in this directory is not an endorsement.